https://www.fool.com/investing/2018/11/05/heres-why-clovis-oncology-stock-dropped-a-whopping.aspx
Here's Why Clovis Oncology Stock Dropped a Whopping 60.4% in October | The Motley Fool
Nov 5, 2018 - Three separate unfavorable events sent investors packing. Were things really that bad?
the motley foolclovis oncologydropped astockwhopping
https://newsquantified.com/tickers/clvs/earnings
Clovis Oncology, Inc. (CLVS) earnings reactions
Quarterly and annual CLVS reports and results, each read against the price at its own news timestamp.
clovis oncologyincclvsearningsreactions
https://www.biospace.com/clovis-oncology-announces-availability-and-reimbursement-for-rubraca-rucaparib-tablets-for-women-with-relapsed-ovarian-cancer-in-france
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women...
Feb 3, 2020 - Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor...
clovis oncologyannouncesavailabilityreimbursementrucaparib
https://www.willkie.com/news/2015/07/clovis-oncology-announces-275m-stock-offering
Clovis Oncology Announces $316.2 Million Stock Offering | Willkie Farr & Gallagher LLP
Willkie represents biopharmaceutical company Clovis Oncology, Inc. in its underwritten public offering of 3,525,641 shares of its common stock. On July 8,...
willkie farr gallagherclovis oncologystock offeringannouncesmillion